Obexelimab Biosimilar
REQUEST MORE INFO
Catalogue No: abx831323
Price:
US$435.00
(Size: 100 µg)
Orders to United States ship from United States
Add to Cart
Buy It Now
GET A QUOTE
Documents
Datasheet SDS
Obexelimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD19, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Obexelimab (XmAb5871) is a first-in-class monoclonal antibody that targets CD19 with its variable domain and uses the XmAb immune inhibitory Fc domain to target FcγRIIb, a receptor that inhibits B cell function. Obexelimab is the first drug candidate to our knowledge that targets FcγRIIb inhibition.
Research Articles on CD19
| Target | CD19 |
| Research Area | Chimeric Monoclonal Antibodies, Biosimilars |
| Clonality | Monoclonal |
| Reactivity | Human |
| Expression | Recombinant |
| Tested Applications | ELISA |
| Host | Human, Mouse |
| Recommended dilutions | Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Isotype | IgG1 Kappa |
| Form | Liquid |
| Purity | > 95% |
| Purification | Purified from cell culture supernatants by Protein A/G chromatography. |
| Storage | Store at 4°C for up to 2 weeks. Aliquot and store at -20°C for long term storage. Avoid repeated freeze/thaw cycles. |
| Shelf Life | 12 months. |
| Buffer | 0.01 M PBS, pH 7.4. |
| CAS Number | 1690307-05-1 |
| Concentration | Batch-dependent, typically between 0.5-2.0 mg/ml. |
| Availability | Shipped within 5-10 working days. |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
